Danish Biotech Weekly – Week 17

In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Evaxion Biotech presented clinical data, Genmab announced net sales of Darzalex, and 2Curex published its annual report of 2022. 8 of the 20 listed, Danish biotech companies have published news the past week. 4 of the companies had a positive development in their share price for the week and 5 companies have had a positive share price performance year to date.

Company news the past week

Ascendis Pharma

No news the past week


No news the past week


April business update – the business strategy (LINK)

CS Medica

No news the past week


No news the past week

Evaxion Biotech

Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints (LINK)


ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue (LINK)


No news the past week


argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology (LINK)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023 (LINK)

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen (LINK)


No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No News the past week


No news the past week

Scandion Oncology

No news past week

SynAct Pharma

SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023 (LINK)


No news past week

Zealand Pharma

Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors, Corporate Management and employees for 2023 (LINK)

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (LINK)

Y-mAbs Therapeutics

Y-mAbs Announces Presentation of Naxitamab data at AACR (LINK)


2cureX publishes the annual report for the fiscal year 2022 (LINK)



Most of the Danish Biotech stocks fell during last week. Thus, the average return was -4.5%. Only 4 of them had a positive return. Biosergen AB became the best performing stock followed by Zealand Pharma A/S. On the other hand, ViroGates A/S and Pila Pharma A/S became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Zealand Pharma A/S and Fluoguide AB have performed very well.

Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.